ATNM - Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy

Actinium Pharmaceuticals' (ATNM) collaborator, Memorial Sloan Kettering Cancer Center ((MSK)) has commenced patient enrollment in Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted CAR T-cell 19-28z.Iomab-ACT is a low dose version of Actinium's Phase 3 drug candidate Iomab-B, a CD45 targeting antibody radiation conjugate.The scientific rationale for this trial builds on preclinical data published in 2020 and is further supported by clinical observations from the SIERRA trial to justify combining MSK's 19-28z CAR T-cell therapy with Iomab-ACT.Manufacturing of patient CAR T-cells has commenced and patient conditioning with Iomab-ACT followed by 19-28z CAR T-cell infusion is expected early in Q2, with proof-of-concept data expected in H2.

For further details see:

Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy